Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - CTI BIOPHARMA CORPFinancial_Report.xls
10-Q - FORM 10-Q - CTI BIOPHARMA CORPd10q.htm
EX-4.6 - FORM OF COMMON STOCK PURCHASE WARRANT, DATED JULY 27, 2010 - CTI BIOPHARMA CORPdex46.htm
EX-32 - CERTIFICATION OF CEO AND CFO PURSUANT TO SECTION 906 - CTI BIOPHARMA CORPdex32.htm
EX-4.5 - FORM OF SERIES 6 PREFERRED STOCK CERTIFICATE - CTI BIOPHARMA CORPdex45.htm
EX-31.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 - CTI BIOPHARMA CORPdex312.htm
EX-10.4 - FORM OF WARRANT EXCHANGE AGREEMENT, DATED JULY 25, 2010 - CTI BIOPHARMA CORPdex104.htm
EX-10.3 - FORM OF SECURITIES PURCHASE AGREEMENT, DATED JULY 25, 2010 - CTI BIOPHARMA CORPdex103.htm
EX-31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 - CTI BIOPHARMA CORPdex311.htm
EX-10.5 - LETTER AGREEMENT, DATED JULY 25, 2010 - CTI BIOPHARMA CORPdex105.htm
EX-10.6 - DRUG PRODUCT MANUFACTURING SUPPLY AGREEMENT, DATED JULY 13, 2010 - CTI BIOPHARMA CORPdex106.htm

Exhibit No. 15

August 6, 2010

Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Commissioners:

We are aware that our report dated August 6, 2010 on our review of interim financial information of Cell Therapeutics, Inc. for the six month period ended June 30, 2010 included in the Company’s quarterly report on Form 10-Q for the quarter ended June 30, 2010 is incorporated by reference in the Registration Statements of Cell Therapeutics, Inc. on Forms S-3 (File Nos. 333-130411, 333-131533, 333-130004, 333-36038, 333-41300, 333-67906, 333-36603, 333-38431, 333-108926, 333-112681, 333-138170, 333-134126, 333-14352, 333-149980, 333-149981, 333-149982, 333-152170, 333-152171, 333-152172, 333-160969, 333-158272, 333-157376, and 333-153358) and on Form S-8 (File No. 333-65200, 333-58957, 333-35919, 333-97015, 333-106568, 333-106571, 333-112791, 333-118016, 333-146624, 333-152168, 333-158260 and 333-162955).

Yours very truly,

/s/ Stonefield Josephson, Inc.